Figure 2
Detection of post-alloHSCT human serum antibodies binding to primary B-CLL cells. PBMCs (5 × 105, consisting of > 85% B-CLL cells) harvested before induction chemotherapy from alloHSC transplant recipients patients A and B were incubated with plasma samples collected from each patient at the indicated time points. Plasma from alloHSCT donor (donor) or healthy volunteers (control) was included. The assay procedure described for Figure 1 was followed. By using a CD3-FITC/CD19-PE 2-color reagent, PBMCs were gated into B cells (dominated by B-CLL cells) and T cells. B-cell (■) and T cell–surface reactivities (□) are depicted as MFI for patient A (left) and patient B (right). Wk indicates, weeks; m, months.
